Ever Supreme Bio-Technology

Ever Supreme Bio-Technology is a leading Taiwanese biotechnology company focused on the development of innovative cell therapies for cancer and regenerative medicine. The company utilizes two core technology platforms: Umbilical Cord Mesenchymal Stem Cells (UMSC) and immune cell therapies, including CAR-T, Dendritic Cells (DC), and Cytokine-Induced Killer (CIK) cells. Ever Supreme is notable for being the first company in Taiwan to receive approval for multiple cell therapy products under the country's Regulations Governing the Application of Specific Medical Care Techniques. Their clinical pipeline targets high-unmet-need indications such as acute myocardial infarction, ischemic stroke, and solid tumors. The company operates a state-of-the-art PIC/S GMP-certified cell processing facility to support both its internal pipeline and contract manufacturing services.